CELA1

Chymotrypsin-like elastase family member 1 · Q9UNI1 · CELA1 on Sugi Atlas →

3,637 patent compounds predicted against CELA1, 2,711 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Polyozellin (SCHEMBL2454411)	1.00	2/20
SCHEMBL2417272	0.55	2/20
SCHEMBL3137273	0.50	2/20
SCHEMBL3600800	0.46	2/20
SCHEMBL3887841	0.45	2/20
SCHEMBL7795084	0.44	2/20
SCHEMBL6768274	0.42	2/20
SCHEMBL721909	0.40	2/20
SCHEMBL4647729	0.40	2/20
SCHEMBL5034651	0.39	2/20
SCHEMBL4479467	0.37	2/20
Telaprevir (SCHEMBL183996)	1.00	1/20
Telaprevir (SCHEMBL184177)	1.00	1/20
Telaprevir (SCHEMBL349033)	1.00	1/20
Telaprevir (SCHEMBL464285)	1.00	1/20
Telaprevir (SCHEMBL1709083)	1.00	1/20
Telaprevir (SCHEMBL2308998)	1.00	1/20
Telaprevir (SCHEMBL2329513)	1.00	1/20
Telaprevir (SCHEMBL3456255)	1.00	1/20
Telaprevir (SCHEMBL3457856)	1.00	1/20

Clinical trials — most relevant to CELA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function	PHASE4	COMPLETED
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema	PHASE2/PHASE3	COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema	PHASE2/PHASE3	WITHDRAWN
STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19	PHASE3	COMPLETED
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency	PHASE3	COMPLETED
Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency	PHASE2	COMPLETED
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients	PHASE2	COMPLETED
Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation	PHASE2	COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery	PHASE1/PHASE2	UNKNOWN
Phase 2 Study to Assess the Safety and Efficacy of ANG003	PHASE2	RECRUITING
Effects of Topical SLPI on Skin Wounds	PHASE1	COMPLETED
Acute Pancreatitis Targets (APT) Study	nan	COMPLETED
Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome	nan	WITHDRAWN
Genomic Research in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD)	nan	COMPLETED
Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations	nan	RECRUITING
Pancreatic Exocrine Insufficiency in Acute Pancreatitis	nan	COMPLETED
Exocrine Pancreatic Function Testing in Cystic Fibrosis	nan	UNKNOWN
PE-1 in the Diagnosis of Pancreatic Exocrine Insufficiency	nan	COMPLETED
Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating	nan	COMPLETED
Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy	nan	COMPLETED
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and Exocrine Pancreatic Dysfunction in Type 1 Diabetes	nan	COMPLETED
Esophageal String Test in Eosinophilic Esophagitis	nan	ACTIVE_NOT_RECRUITING
Effect Of Pulmonary Rehabilitation in Patients With Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
The Use of High Resolution Chest Computed Tomography in Alpha-1 Antitrypsin Deficiency	nan	COMPLETED
Post Acute Pancreatitis Pancreatic Exocrine Insufficiency	nan	COMPLETED
Inhaled A1AT in Adult Stable Bronchiectasis	nan	COMPLETED
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency	nan	COMPLETED
Gastrointestinal Study at Orkambi Therapy in CF Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CELA1 binder may also engage these)

Protein	Name	Similarity
O46644	—	0.996	O46644 →
Q5R1M5	—	0.996	Q5R1M5 →
Q867B0	—	0.995	Q867B0 →
Q28153	—	0.994	Q28153 →
P00773	—	0.992	P00773 →
Q91X79	—	0.992	Q91X79 →
P08218	—	0.989	P08218 →
P00772	—	0.987	P00772 →
P05208	—	0.984	P05208 →
Q29461	—	0.983	Q29461 →
P08419	—	0.979	P08419 →
P08217	—	0.979	P08217 →
P00774	—	0.978	P00774 →
Q7SIG3	—	0.977	Q7SIG3 →
P05805	—	0.973	P05805 →
P06871	—	0.969	P06871 →
Q90628	—	0.965	Q90628 →
P08861	—	0.965	P08861 →
P70059	—	0.965	P70059 →
P16049	—	0.965	P16049 →
PRSS1	Serine protease 1	0.965	landscape →
Q91041	—	0.964	Q91041 →
P35031	—	0.964	P35031 →
Q90627	—	0.964	Q90627 →
P80646	—	0.963	P80646 →
Q7M3E1	—	0.961	Q7M3E1 →
P35044	—	0.961	P35044 →
O19023	—	0.961	O19023 →
P08426	—	0.960	P08426 →
P35003	—	0.960	P35003 →